Tracon Pharmaceuticals, Inc. Submits Form 25-NSE to SEC
Tracon Pharmaceuticals, Inc. recently filed a Form 25-NSE with the Securities and Exchange Commission (SEC), indicating the voluntary delisting of its securities from the Nasdaq Stock Market. This move signifies the company’s decision to withdraw its shares from public trading on the exchange. Tracon Pharmaceuticals, Inc. will now focus on alternative trading platforms or go private, impacting its liquidity and visibility in the public market.
Tracon Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of targeted therapeutics for cancer and age-related macular degeneration. The company’s innovative approach to drug development aims to address unmet medical needs in oncology and ophthalmology. For more information on Tracon Pharmaceuticals, Inc., please visit their website at https://www.traconpharma.com/.
Form 25-NSE is a notification of the removal from listing and registration of matured, redeemed, or retired securities. Companies file this form to voluntarily delist their securities from a national securities exchange, signaling a significant change in their trading status. This form is crucial for investors and stakeholders to stay informed about the company’s decision to transition out of public trading platforms.
Read More:
Tracon Pharmaceuticals, Inc. Submits Form 25-NSE to SEC (0001394319) – Latest News
